Rufinamide NEW
| Price | $56 | $93 | $179 |
| Package | 25mg | 50mg | 100mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-26 |
Product Details
| Product Name: Rufinamide | CAS No.: 106308-44-5 |
| Purity: 99.77% | Supply Ability: 10g |
| Release date: 2026/05/26 |
Product Introduction
Bioactivity
| Name | Rufinamide |
| Description | Rufinamide (E 2080), a triazole derivative, is used as voltage-gated sodium channel blocker for the treatment of seizure disorders. |
| In vitro | Rufinamide effectively suppresses maximal electroshock (MES)-induced tonic convulsions in mice (ED50 = 23.9 mg/kg) and rats (ED50 = 6.1 mg/kg). Additionally, Rufinamide inhibits pentylenetetrazol-(ED 50=54.0), bicuculline-(ED 50=50.5), and picrotoxin (ED 50=76.3 mg/kg) provoked clonic seizures in mice. Furthermore, it prevents pentylenetetrazole-induced epileptic seizures in mice at an effective dose of 45.8 mg/kg (ED50). |
| In vivo | Rufinamide inhibits sodium-dependent action potentials in neurons, potentially exhibiting membrane stabilizing effects. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 16.67 mg/mL (69.99 mM), Sonication is recommended. 10% DMSO+90% Corn Oil : 1.5 mg/mL (6.3 mM), Sonication is recommended. Ethanol : < 1 mg/mL (insoluble or slightly soluble) |
| Keywords | SodiumChannel | Sodium Channel | Rufinamide | RUF-331 | RUF331 | Inhibitor | inhibit | E-2080 | E2080 | CGP-33101 | CGP33101 |
| Inhibitors Related | Phenytoin sodium | Procaine | Ranolazine dihydrochloride | Tetracaine hydrochloride | Lidocaine | Safinamide | Permethrin | Valproic Acid | L-Aspartic aicd sodium | Lidocaine hydrochloride | Mebeverine hydrochloride | Dibucaine |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Neuroprotective Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
-
CAS:97-74-5
-
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP6Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2026-06-27 | ||
|
VIP1Y
|
Jinan Ruitong Biotech Co., Ltd.
|
2026-06-08 | ||
| $5.00 |
Wuhan JiyunZen Tech Co., Ltd.
|
2026-04-10 | ||
| $30.00 |
Longyan Tianhua Biological Technology Co., Ltd
|
2020-11-16 | ||
| $1.00 |
VIP8Y
|
Career Henan Chemical Co
|
2019-07-06 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY